We are live on ! Find out more
CMMB

Chemomab Therapeutics
CMMB

17 hedge funds and large institutions have $1.47M invested in Chemomab Therapeutics in 2023 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

250% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 2

42% more funds holding

Funds holding: 12 → 17 (+5)

0.04% more ownership

Funds ownership: 0.29% → 0.33% (+0.04%)

35% less capital invested

Capital invested by funds: $2.27M → $1.47M (-$801K)

50% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 2

Holders
17
Holders Change
+5
Holders Change %
+41.67%
% of All Funds
0.25%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
1
Reduced
2
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$93.4K
2
Two Sigma Investments
Two Sigma Investments
New York
+$37.1K
3
Two Sigma Advisers
Two Sigma Advisers
New York
+$23.3K
4
Citadel Advisors
Citadel Advisors
Florida
+$21.5K
5
XT
XTX Topco
Cayman Islands
+$19.1K

Top Sellers

Rank Fund Capital Flow
1
ASN
Advisory Services Network
Georgia
-$4.2K
2
NFSG
Newbridge Financial Services Group
Florida
-$985
3
Osaic Holdings
Osaic Holdings
Arizona
-$785
4
UBS Group
UBS Group
Switzerland
-$126
Name Holding Trade Value Shares
Change 		Change in
Stake
O
1
OrbiMed
New York
$1.14M – – –
IC
2
Ikarian Capital
Texas
$109K – – –
Morgan Stanley
3
Morgan Stanley
New York
$72.3K +$93.4K +35,458 New
Two Sigma Investments
4
Two Sigma Investments
New York
$28.7K +$37.1K +14,076 New
Two Sigma Advisers
5
Two Sigma Advisers
New York
$18.1K +$23.3K +8,850 New
Citadel Advisors
6
Citadel Advisors
Florida
$16.7K +$21.5K +8,169 New
KPWS
7
Kestra Private Wealth Services
Texas
$15.9K – – –
XT
8
XTX Topco
Cayman Islands
$14.8K +$19.1K +7,262 New
BFM
9
Boothbay Fund Management
New York
$13.5K – – –
VF
10
Virtu Financial
New York
$13K +$17K +6,452 New
Millennium Management
11
Millennium Management
New York
$10K +$13K +4,925 New
RhumbLine Advisers
12
RhumbLine Advisers
Massachusetts
$9.5K +$10.4K +3,946 +555%
Geode Capital Management
13
Geode Capital Management
Massachusetts
$5.99K – – –
ASN
14
Advisory Services Network
Georgia
$2.44K -$4.2K -1,596 -57%
Osaic Holdings
15
Osaic Holdings
Arizona
$297 -$785 -298 -67%
MWA
16
Moser Wealth Advisors
Washington
$255 – – –
Qube Research & Technologies (QRT)
17
Qube Research & Technologies (QRT)
United Kingdom
$22 – – –
NFSG
18
Newbridge Financial Services Group
Florida
– -$985 -275 Closed
UBS Group
19
UBS Group
Switzerland
– -$126 -35 Closed

CMMB Hedge Fund Activity: Q4 2023 in Review

17 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Chemomab Therapeutics (CMMB) for Q4 2023, worth a combined $1.47M — down 35% from $2.27M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new CMMB positions and 2 closed out — a net gain of 5 holders — while 1 added to existing stakes and 2 trimmed.

The largest buyer was Morgan Stanley, opening a new position worth an estimated $93.4K. The largest seller was Advisory Services Network, cutting an estimated $4.2K.

  • 17 institutional investors held Chemomab Therapeutics (CMMB) as of Q4 2023, up from 12 in Q3 2023.
  • Funds reported $1.47M of Chemomab Therapeutics stock for Q4 2023, down 35% quarter-over-quarter.
  • 7 funds opened new Chemomab Therapeutics positions in Q4 2023 and 2 closed out, a net change of +5 holders.
  • The largest Chemomab Therapeutics buyer in Q4 2023 was Morgan Stanley, an estimated $93.4K added.
  • The largest Chemomab Therapeutics seller in Q4 2023 was Advisory Services Network, an estimated $4.2K sold.

Based on aggregated 13F filings for Q4 2023.